{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T00:04:25Z","timestamp":1777161865664,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000646","name":"Japan Society for the Promotion of Science London","doi-asserted-by":"publisher","award":["17K07175"],"award-info":[{"award-number":["17K07175"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-023-02042-5","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T09:22:50Z","timestamp":1683796970000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Heat shock factor 1 is a promising therapeutic target against adult T-cell leukemia"],"prefix":"10.1007","volume":"40","author":[{"given":"Chie","family":"Ishikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3998-6711","authenticated-orcid":false,"given":"Naoki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"2042_CR1","doi-asserted-by":"publisher","first-page":"e517","DOI":"10.1016\/S1470-2045(14)70202-5","volume":"15","author":"K Ishitsuka","year":"2014","unstructured":"Ishitsuka K, Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol. 2014;15:e517\u201326.","journal-title":"Lancet Oncol"},{"key":"2042_CR2","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3389\/fmicb.2012.00322","volume":"3","author":"M Iwanaga","year":"2012","unstructured":"Iwanaga M, Watanabe T, Yamaguchi K. Adult T-cell leukemia: a review of epidemiological evidence. Front Microbiol. 2012;3:322.","journal-title":"Front Microbiol"},{"key":"2042_CR3","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.3389\/fmicb.2020.01207","volume":"11","author":"K Tsukasaki","year":"2020","unstructured":"Tsukasaki K, Mar\u00e7ais A, Nasr R, Kato K, Fukuda T, Hermine O, Bazarbachi A. Diagnostic approaches and established treatments for adult T cell leukemia lymphoma. Front Microbiol. 2020;11:1207.","journal-title":"Front Microbiol"},{"key":"2042_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113846","volume":"226","author":"MK Kurop","year":"2021","unstructured":"Kurop MK, Huyen CM, Kelly JH, Blagg BSJ. The heat shock response and small molecule regulators. Eur J Med Chem. 2021;226: 113846.","journal-title":"Eur J Med Chem"},{"key":"2042_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3892\/ol.2016.4624","volume":"12","author":"C Ishikawa","year":"2016","unstructured":"Ishikawa C, Senba M, Mori N. Efficiency of AUY922 in mice with adult T-cell leukemia\/lymphoma. Oncol Lett. 2016;12:387\u201392.","journal-title":"Oncol Lett"},{"key":"2042_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.canlet.2009.04.012","volume":"284","author":"R Kurashina","year":"2009","unstructured":"Kurashina R, Ohyashiki JH, Kobayashi C, Hamamura R, Zhang Y, Hirano T, Ohyashiki K. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin\/TCF7L2 pathway in adult T cell leukemia cells. Cancer Lett. 2009;284:62\u201370.","journal-title":"Cancer Lett"},{"key":"2042_CR7","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1111\/cas.12540","volume":"105","author":"H Taniguchi","year":"2014","unstructured":"Taniguchi H, Hasegawa H, Sasaki D, Ando K, Sawayama Y, Imanishi D, Taguchi J, Imaizumi Y, Hata T, Tsukasaki K, Uno N, Morinaga Y, Yanagihara K, Miyazaki Y. Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia-lymphoma cells. Cancer Sci. 2014;105:1601\u20138.","journal-title":"Cancer Sci"},{"key":"2042_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.860320","volume":"12","author":"AM Cyran","year":"2022","unstructured":"Cyran AM, Zhitkovich A. Heat shock proteins and HSF1 in cancer. Front Oncol. 2022;12: 860320.","journal-title":"Front Oncol"},{"key":"2042_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188390","volume":"1874","author":"G Wang","year":"2020","unstructured":"Wang G, Cao P, Fan Y, Tan K. Emerging roles of HSF1 in cancer: cellular and molecular episodes. Biochim Biophys Acta Rev Cancer. 2020;1874: 188390.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2042_CR10","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1074\/jbc.M110.179440","volume":"286","author":"YJ Yoon","year":"2011","unstructured":"Yoon YJ, Kim JA, Shin KD, Shin DS, Han YM, Lee YJ, Lee JS, Kwon BM, Han DC. KRIBB11 inhibits HSP70 synthesis through inhibition of heat shock factor 1 function by impairing the recruitment of positive transcription elongation factor b to the hsp70 promoter. J Biol Chem. 2011;286:1737\u201347.","journal-title":"J Biol Chem"},{"key":"2042_CR11","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.4049\/jimmunol.157.9.3980","volume":"157","author":"C Zhang","year":"1996","unstructured":"Zhang C, Ao Z, Seth A, Schlossman SF. A mitochondrial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells. J Immunol. 1996;157:3980\u20137.","journal-title":"J Immunol"},{"key":"2042_CR12","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1182\/blood.V87.8.3410.bloodjournal8783410","volume":"87","author":"N Mori","year":"1996","unstructured":"Mori N, Prager D. Transactivation of the interleukin-1\u03b1 promoter by human T-cell leukemia virus type I and type II Tax proteins. Blood. 1996;87:3410\u20137.","journal-title":"Blood"},{"key":"2042_CR13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/BF00300234","volume":"24","author":"MM Tomayko","year":"1989","unstructured":"Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989;24:148\u201354.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2042_CR14","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s10637-022-01250-6","volume":"40","author":"C Ishikawa","year":"2022","unstructured":"Ishikawa C, Mori N. Exportin-1 is critical for cell proliferation and survival in adult T cell leukemia. Invest New Drugs. 2022;40:718\u201327.","journal-title":"Invest New Drugs"},{"key":"2042_CR15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.molcel.2020.08.020","volume":"80","author":"SM Rubin","year":"2020","unstructured":"Rubin SM, Sage J, Skotheim JM. Integrating old and new paradigms of G1\/S control. Mol Cell. 2020;80:183\u201392.","journal-title":"Mol Cell"},{"key":"2042_CR16","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1038\/sj.onc.1204304","volume":"20","author":"R Iwanaga","year":"2001","unstructured":"Iwanaga R, Ohtani K, Hayashi T, Nakamura M. Molecular mechanism of cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I. Oncogene. 2001;20:2055\u201367.","journal-title":"Oncogene"},{"key":"2042_CR17","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.3390\/ijms23095005","volume":"23","author":"N Koo","year":"2022","unstructured":"Koo N, Sharma AK, Narayan S. Therapeutics targeting p53-MDM2 interaction to induce cancer cell death. Int J Mol Sci. 2022;23:5005.","journal-title":"Int J Mol Sci"},{"key":"2042_CR18","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/genes10030244","volume":"10","author":"L Garc\u00eda-Guti\u00e9rrez","year":"2019","unstructured":"Garc\u00eda-Guti\u00e9rrez L, Delgado MD, Le\u00f3n J. MYC oncogene contributions to release of cell cycle brakes. Genes. 2019;10:244.","journal-title":"Genes"},{"key":"2042_CR19","doi-asserted-by":"publisher","first-page":"31767","DOI":"10.18632\/oncotarget.5167","volume":"6","author":"S Ganguly","year":"2015","unstructured":"Ganguly S, Home T, Yacoub A, Kambhampati S, Shi H, Dandawate P, Padhye S, Saluja AK, McGuirk J, Rao R. Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia. Oncotarget. 2015;6:31767\u201379.","journal-title":"Oncotarget"},{"key":"2042_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2020.153243","volume":"76","author":"S Manandhar","year":"2020","unstructured":"Manandhar S, Kabekkodu SP, Pai KSR. Aberrant canonical Wnt signaling: phytochemical based modulation. Phytomedicine. 2020;76: 153243.","journal-title":"Phytomedicine"},{"key":"2042_CR21","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/ijc.31963","volume":"144","author":"G Augello","year":"2019","unstructured":"Augello G, Emma MR, Cusimano A, Azzolina A, Mongiov\u00ec S, Puleio R, Cassata G, Gulino A, Belmonte B, Gramignoli R, Strom SC, McCubrey JA, Montalto G, Cervello M. Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma. Int J Cancer. 2019;144:2613\u201324.","journal-title":"Int J Cancer"},{"key":"2042_CR22","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.3389\/fmicb.2017.02686","volume":"8","author":"H Gazon","year":"2018","unstructured":"Gazon H, Barbeau B, Mesnard J-M, Peloponese J-M Jr. Hijacking of the AP-1 signaling pathway during development of ATL. Front Microbiol. 2018;8:2686.","journal-title":"Front Microbiol"},{"key":"2042_CR23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10637-020-01007-z","volume":"39","author":"C Ishikawa","year":"2021","unstructured":"Ishikawa C, Senba M, Mori N. Importin \u03b21 regulates cell growth and survival during adult T cell leukemia\/lymphoma therapy. Invest New Drugs. 2021;39:317\u201329.","journal-title":"Invest New Drugs"},{"key":"2042_CR24","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1038\/sj.onc.1210984","volume":"27","author":"T Nakayama","year":"2008","unstructured":"Nakayama T, Hieshima K, Arao T, Jin Z, Nagakubo D, Shirakawa AK, Yamada Y, Fujii M, Oiso N, Kawada A, Nishio K, Yoshie O. Aberrant expression of Fra-2 promotes CCR4 expression and cell proliferation in adult T-cell leukemia. Oncogene. 2008;27:3221\u201332.","journal-title":"Oncogene"},{"key":"2042_CR25","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.3390\/cells11182778","volume":"11","author":"J Zhang","year":"2022","unstructured":"Zhang J, Li H, Liu Y, Zhao K, Wei S, Sugarman ET, Liu L, Zhang G. Targeting HSP90 as a novel therapy for cancer: mechanistic insights and translational relevance. Cells. 2022;11:2778.","journal-title":"Cells"},{"key":"2042_CR26","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1074\/jbc.RA117.000634","volume":"293","author":"LC Cesa","year":"2018","unstructured":"Cesa LC, Shao H, Srinivasan SR, Tse E, Jain C, Zuiderweg ERP, Southworth DR, Mapp AK, Gestwicki JE. X-linked inhibitor of apoptosis protein (XIAP) is a client of heat shock protein 70 (Hsp70) and a biomarker of its inhibition. J Biol Chem. 2018;293:2370\u201380.","journal-title":"J Biol Chem"},{"key":"2042_CR27","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1002\/ijc.20954","volume":"115","author":"H Kawakami","year":"2005","unstructured":"Kawakami H, Tomita M, Matsuda T, Ohta T, Tanaka Y, Fujii M, Hatano M, Tokuhisa T, Mori N. Transcriptional activation of survivin through the NF-\u03baB pathway by human T-cell leukemia virus type I tax. Int J Cancer. 2005;115:967\u201374.","journal-title":"Int J Cancer"},{"key":"2042_CR28","doi-asserted-by":"publisher","first-page":"6853","DOI":"10.1038\/sj.onc.1203239","volume":"18","author":"HL Pahl","year":"1999","unstructured":"Pahl HL. Activators and target genes of Rel\/NF-\u03baB transcription factors. Oncogene. 1999;18:6853\u201366.","journal-title":"Oncogene"},{"key":"2042_CR29","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1158\/1940-6207.CAPR-10-0037","volume":"3","author":"S Reuter","year":"2010","unstructured":"Reuter S, Prasad S, Phromnoi K, Ravindran J, Sung B, Yadav VR, Kannappan R, Chaturvedi MM, Aggarwal BB. Thiocolchicoside exhibits anticancer effects through downregulation of NF-\u03baB pathway and its regulated gene products linked to inflammation and cancer. Cancer Prev Res. 2010;3:1462\u201372.","journal-title":"Cancer Prev Res"},{"key":"2042_CR30","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1126\/science.281.5383.1680","volume":"281","author":"C-Y Wang","year":"1998","unstructured":"Wang C-Y, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-\u03baB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998;281:1680\u20133.","journal-title":"Science"},{"key":"2042_CR31","doi-asserted-by":"publisher","first-page":"59950","DOI":"10.18632\/oncotarget.19048","volume":"8","author":"H-C Zheng","year":"2017","unstructured":"Zheng H-C. The molecular mechanisms of chemoresistance in cancers. Oncotarget. 2017;8:59950\u201364.","journal-title":"Oncotarget"},{"key":"2042_CR32","doi-asserted-by":"publisher","first-page":"14374","DOI":"10.1073\/pnas.202445099","volume":"99","author":"N Mitsiades","year":"2002","unstructured":"Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA. 2002;99:14374\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2042_CR33","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1158\/1078-0432.CCR-11-1000","volume":"18","author":"L Neckers","year":"2012","unstructured":"Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res. 2012;18:64\u201376.","journal-title":"Clin Cancer Res"},{"key":"2042_CR34","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/leu.2008.111","volume":"22","author":"T St\u00fchmer","year":"2008","unstructured":"St\u00fchmer T, Z\u00f6llinger A, Siegmund D, Chatterjee M, Grella E, Knop S, Kort\u00fcm M, Unzicker C, Jensen MR, Quadt C, Ch\u00e8ne P, Schoepfer J, Garc\u00eda-Echeverr\u00eda C, Einsele H, Wajant H, Bargou RC. Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia. 2008;22:1604\u201312.","journal-title":"Leukemia"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02042-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-023-02042-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02042-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T02:30:34Z","timestamp":1685068234000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-023-02042-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["2042"],"URL":"https:\/\/doi.org\/10.1007\/s12032-023-02042-5","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]},"assertion":[{"value":"15 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"172"}}